Tailong Health Industry Investment Co., Ltd announced that it expects to receive CNY 220 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd
November 10, 2022
Share
Tailong Health Industry Investment Co., Ltd announced that it will receive CNY 220,000,000 in an equity round of funding on November 10, 2022. The transaction will include participation from returning investor Henan Taloph Pharmaceutical Stock Co.,Ltd, which will retain its existing stake of 100%. Out of the total proceeds CNY 29,200,000 will go towards registered capital and remaining CNY 190,800,000 will go towards capital reserve. Post completion of transaction, the registered capital of the company will increase from CNY 160,800,000 to CNY 190,000,000. The transaction has been approved by the board of directors of the investor in its tenth meeting of the ninth session of the board of directors.
On November 21, 2022, the company announced that it has completed the change of business registration of its capital increase.
HENANTALOPHPHARMACEUTICALSTOCKCO., LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company provides oral solutions, transfusion and tablets, which are applied in the treatment of cold, diabetes and virus infection. The Company's main products include Shuanghuanglian oral liquid products, double gold agents, Haberffine tablets and compound Yimu oral solutions, among others. The Company distributes its products mainly within domestic market.
Tailong Health Industry Investment Co., Ltd announced that it expects to receive CNY 220 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd